Abstract Library

#2872 Characteristics of the Immunophenotype and the Status of Receptors for Somatostatin Type 2 and 5 of Typical and Atypical Carcinoids of the Lung

Introduction: Carcinoids of the lung are a wide range of tumors with various malignancy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Gurevich L, Voronkova I, Ashevskay V, Bondarenco E, Fedorov D,

Keywords: lung, carcinoid, immunophenotype,

#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.

Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rizza S

Authors: Rizza S, Canavese G, Ribaldone D, Cassoni P, Astegiano M,

Keywords: Neuroendocrine tumor, NET, inflammatory bowel disease, Chromogranin, Echo-endoscopy, EUS, IBD,

#1435 Gastric Neuroendocrine Tumors - From Clinicopathologic to Immunophenotype Features

Introduction: Type 3 Gastric Neuroendocrine tumors (GNET3) natured in the absence of a specific gastric background of pathologic changes, while with poorer outcome due to a high rate of distant metastasis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Ji Y, Xie Y, Sun Y, Wang H, Chen S,

Keywords: gastric, neuroendocrine tumor, mTOR,

#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors

Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Grabowski P

Authors: Grabowski P, Joehrens K, Arsenic R, Kaemmerer D, Hummel M,

Keywords: Immunophenotype, PD-L1, poorly differentiated NECs, immunotherapy,